Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trialJane C. Burns, Nichole Samuy, James B. Wood et al.|The Lancet Child & Adolescent Health|2021Cited by 113
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki diseaseSamantha C. Roberts, Sylvia H. Yeh, Sonia Jain et al.|Contemporary Clinical Trials|2019Cited by 25
Analytical and clinical validation of direct detection of antimicrobial resistance markers by plasma microbial cell-free DNA sequencingFred C. Christians, Frederick S. Nolte, Jamilla Akhund‐Zade et al.|Journal of Clinical Microbiology|2024Cited by 21
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki diseaseSamantha C. Roberts, Sylvia H. Yeh, Sonia Jain et al.|Author eBooks|2019Cited by 1
Analytical and Clinical Validation of Direct Detection of Antimicrobial Resistance Markers by Plasma Microbial Cell-free DNA SequencingFred C. Christians, Frederick S. Nolte, Jamilla Akhund‐Zade et al.|medRxiv|2024Cited by 1